Millie Das, MD

Explore how deeper DNA/RNA testing, trial referrals, and emerging ADC combos reshape EGFR lung cancer care despite access hurdles.

Experts share how to spot and manage cancer therapy toxicities—from pneumonitis to skin and eye issues—balancing efficacy and quality of life.

How EGFR lung cancer therapies impact daily life—managing fatigue, rash, paronychia, and when to pause or reduce treatment.

Explore EGFR lung cancer next-line choices after osimertinib plus chemo—when to rechallenge platinum, use amivantamab, or try dato‑DXd.

Expert guide to sequencing EGFR lung cancer treatment after osimertinib+chemo: chemo rechallenge, amivantamab options, dato‑DXd.

Experts unpack how tumor burden, ctDNA, TP53 and patient fitness shape EGFR lung cancer therapy, and what TOP trial data means for combos.

Experts reveal how TP53 co-mutations worsen EGFR lung cancer outcomes and when to intensify first-line therapy with emerging second-line options.

Millie Das, MD, discusses first-line standards of care for patients with extensive-stage and limited-stage small cell lung cancer.

Millie Das, MD, discusses key trials that have advanced treatment for patients who present with non–small cell lung cancer.

Millie Das, MD, of Stanford Cancer Center, discusses the progress in small cell lung cancer treatment.

Millie Das, MD, discusses the current landscape of new and emerging ADCs under investigation in small-cell lung cancer and highlights the phase 2 SWOG S1929 study.